A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Objective: To determine the efficacy and safety of eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS), compared with current treatment options. Design: A systematic review was performed according to the general principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. All study designs were included, except case histories. Participants: All patients diagnosed with aHUS were included; no age restrictions were used. Interventions: Eculizumab compared with current treatment options. Identification of studies: 12 databases were searched. Additional searches were performed through the Food and Drug Administration (FDA) and the Electronic Medicines Compendium websites, Google internet searches and contacting clinical experts. Reference lists of relevant articles were checked for additional studies. Results: 2 small, uncontrolled prospective multinational, multicentre studies and one small uncontrolled multinational, multicentre retrospective study were included. No meta-analyses were performed. Compared with baseline measures, thrombotic microangiopathy event-free status was achieved in 84% of patients in the prospective studies. Adverse events, as documented by enrolling investigators were frequent, with upper-respiratory tract infection affecting a third of patients. No deaths or episodes of meningitis or meningococcal septicaemia occurred in the prospective studies. Results of the study extension phases up to 114 weeks indicate that the benefits of the treatment are sustained. Conclusions: Eculizumab is clinically effective for the treatment of aHUS. Further research is needed to evaluate eculizumab, ideally using patient-related clinical outcomes. If randomised studies are not feasible, study investigators should ensure that the threat of bias is minimised in future studies of eculizumab with respect to the reporting of patient recruitment and selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Hematological Problems in Pediatric Intensive Care
Revel-Vilk, S., Cox, P., Robitaille, N., & Blanchette, V. (2014) · Pediatric and Adolescent Medicine · doi:10.1159/000350346 · Cited by 3,508
Non-Transgenic Mouse Models of Kidney Disease
Rabe, M., & Schaefer, F. (2016) · Nephron · doi:10.1159/000445171 · Cited by 1,922
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.-A., Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., et al. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04760512 · Cited by 714
Research works printed but not linked: 6
- Gasser, 1955, Hamolytisch-uramische syndrome: bilateral Nierenrindennekrosen bei akuten erworbenen hamolytischen Anamien, Schweiz Med Wochenschr, 85, 905
- Legendre C, Babu S, Furman R, et al. Safety & efficacy of eculizamab in aHUS patients resistant to plasma therapy: interim analysis from a phase II trial. J Am Soc Nephrol 2011;21:201.
- Licht, 2011, A phase II study of eculizumab in adolescent/adult patients with atypical hemolytic uremic syndrome (aHUS) receiving chronic plasma exchange/infusion: interim efficacy and safety analysis, Pediatr Nephrol, 26, 1591
- Licht, 2011, A phase II study of eculizumab in patients with atypical hemolytic uremic syndrome (AHUS) receiving chronic plasma exchange/infusion: interim analysis, J Thromb Haemost, 9, 499
- Simonetti, 2011, Eculizumab therapy for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: efficacy and safety outcomes from a retrospective study, Pediatr Nephrol, 26, 1663
- Hillmen, 2003, Eculizumab, a C5 complement-blocking antibody, controls hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) with responses maintained over a prolonged period of therapy, Blood, 102, 509a
Cited by
International, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics
Garred, P., Tenner, A. J., & Mollnes, T. E. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000072 · Cited by 208
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
Rathbone, J., Hoffmann, T., & Glasziou, P. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0067-6 · Cited by 184
“The trial citations of four systematic reviews [1, 18 – 20] retrieved electronically from biomedical database searches (MEDLINE, EMBASE, CINAHL, Cochrane CENTRAL) were used to evaluate Abstrackr.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A.
- Affiliations
- University of Sheffield (GB)
- Imperial College London (GB)
- Corresponding author
- Kaltenthaler, Eva
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2013-11
- Volume
- 3
- Issue
- 11
- Pages
- e003573
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3822313
- OpenAlex
- W2143604857
- Cited by
- 110
- References
- 56
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 5 · 2022: 11 · 2021: 4 · 2020: 9 · 2019: 13 · 2018: 7 · 2017: 9 · 2016: 13 · 2015: 9 · 2014: 10
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc)
- Funders
- Alexion Pharmaceuticals
- Wellcome Trust (WT085226)
- National Institute for Health and Care Research
- Health Technology Assessment Programme
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, atypical hemolytic uremic syndrome, thrombotic microangiopathy, complement inhibition, treatment efficacy, adverse events, upper respiratory tract infection, long-term treatment outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). https://app.cochat.ai/papers/10.1136/bmjopen-2013-003573
- The paper
- Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A. (2013). A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. https://doi.org/10.1136/bmjopen-2013-003573
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.